It shares its label with Ozempic tablets, a newer semaglutide tablet in different strengths, and it is not approved for weight loss.1
What it is
Rybelsus contains the same semaglutide as the Ozempic and Wegovy injections, a GLP-1 receptor agonist.1 What makes a tablet possible is an absorption enhancer called SNAC, salcaprozate sodium; most of the semaglutide is absorbed in the stomach. Even so, only about 0.4% to 1% of the semaglutide in a Rybelsus tablet reaches the blood, against 89% of an injected dose.1,2 That is why a daily tablet holds several milligrams while a weekly injection holds a fraction of one.
How it is taken
Because so little is absorbed, the label's rules for taking it are strict.1
- Take it in the morning on an empty stomach, with no more than 4 ounces of plain water and no other liquid.
- Swallow it whole, without splitting, crushing or chewing it.
- Wait at least 30 minutes before eating, drinking anything or taking other pills by mouth.
The same rules apply to the Wegovy tablet, and our page on how to take the Wegovy pill shows what the absorption studies behind them found.
How the dose climbs
Rybelsus starts at 3 mg a day for 30 days, a dose the label says is not effective for blood sugar control. From day 31 it is 7 mg, and from day 61 it stays at 7 mg or goes to 14 mg if more control is needed. Ozempic tablets follow the same pattern with 1.5, 4 and 9 mg.1 The two tablets are not substitutable milligram for milligram. The label allows a switch between them only after the first 30 days and gives its own table for it, so a switch follows the prescriber's instructions.1
What it did in trials
In the label's 26-week trial of Rybelsus on its own, in adults whose diabetes was not controlled by diet and exercise, HbA1c started at about 8%. It fell by 1.2 points on 7 mg and 1.4 on 14 mg, against 0.3 on placebo. An HbA1c under 7% was reached by 69% and 77%, against 31% on placebo.1
Two trials looked at the heart. The first, PIONEER 6, enrolled 3,183 adults with type 2 diabetes and high cardiovascular risk. It was designed to show that 14 mg did not raise the risk of a first heart attack, stroke or cardiovascular death, and over a median of 16 months it met that goal with a hazard ratio of 0.79. The second, SOUL, enrolled 9,650 adults with type 2 diabetes and heart disease, kidney disease or both. A first major cardiovascular event occurred in 12% on 14 mg and 13.8% on placebo, a hazard ratio of 0.86, or about 14% lower risk.1,3
Side effects and warnings
The most common side effects are in the stomach and gut. In the label's placebo-controlled trials, nausea was reported by 11% on 7 mg and 20% on 14 mg, against 6% on placebo, abdominal pain by 10% and 11% against 4%, and diarrhea by 9% and 10% against 4%.1
Rybelsus carries the boxed warning about thyroid C-cell tumors seen in rodents and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Low blood sugar is a risk when it is combined with insulin or a sulfonylurea.1
Rybelsus in eight lines
| Fact | Rybelsus |
|---|---|
| Active ingredient | Semaglutide |
| Maker | Novo Nordisk |
| Form | Tablet, once a day |
| Doses | 3 mg to start, then 7 or 14 mg |
| Absorbed | About 0.4% to 1% of each tablet |
| Before eating | Wait at least 30 minutes |
| Approved for | Type 2 diabetes, heart risk |
| Approved for weight loss | No |
RYBELSUS and OZEMPIC tablets prescribing information, revised January 2026.1
Related terms
Ozempic is the weekly semaglutide injection for type 2 diabetes, and the Wegovy tablet is the semaglutide tablet approved for weight. Our page on Ozempic and Wegovy compares the injections, and Ozempic side effects gives the rates for the injected form.
Sources
- RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published August 19, 2026; sections 1, 2, 4, 5, 6.1, 12 and 14. dailymed.nlm.nih.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 12.3. accessdata.fda.gov
- ClinicalTrials.gov records NCT02692716 (PIONEER 6) and NCT03914326 (SOUL), sponsor Novo Nordisk A/S; read November 20, 2026. The label reports these trials by registry number. clinicaltrials.gov
Related analyses
How to take the Wegovy pill: the water, the 30-minute wait and the dose steps
Ozempic side effects: how common each one is by dose, and when they ease
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
When to take your GLP-1 shot: time of day, changing the day and time zones
Log each Rybelsus tablet and the 30-minute wait, and see your mornings on one screen.
Open Dose Insider